MediciNova, Inc (NASDAQ:
MNOV) shares climbed 46.2% to $5.13 after the company reported the FDA approval of the second Phase 2 protocol for MN-001 in NASH which targets NASH patients with hypertriglyceridemia. Share volume was 355,000, compared to an all-day average of 8,100
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
